Assembly Biosciences (NASDAQ:ASMB) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Thursday.
Other analysts have also issued reports about the company. Zacks Investment Research upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and set a $72.00 target price for the company in a research note on Tuesday. Jefferies Group raised their price target on Assembly Biosciences to $75.00 and gave the company a “buy” rating in a report on Thursday, March 8th. ValuEngine upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Finally, B. Riley started coverage on Assembly Biosciences in a report on Friday, January 5th. They issued a “neutral” rating and a $35.00 price target on the stock. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $54.25.
Shares of Assembly Biosciences (NASDAQ ASMB) opened at $64.16 on Thursday. Assembly Biosciences has a 12 month low of $18.60 and a 12 month high of $67.36. The firm has a market capitalization of $1,292.84, a price-to-earnings ratio of -21.60 and a beta of 0.57.
In related news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $56.37, for a total value of $56,370.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 3,000 shares of company stock worth $148,270. 19.60% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of ASMB. Jennison Associates LLC boosted its holdings in Assembly Biosciences by 19.6% in the fourth quarter. Jennison Associates LLC now owns 2,120,300 shares of the biopharmaceutical company’s stock valued at $95,944,000 after acquiring an additional 347,025 shares during the last quarter. Farallon Capital Management LLC bought a new position in Assembly Biosciences in the fourth quarter valued at about $11,313,000. State Street Corp bought a new position in Assembly Biosciences in the second quarter valued at about $4,234,000. Emerald Advisers Inc. PA bought a new position in Assembly Biosciences in the fourth quarter valued at about $8,673,000. Finally, BlackRock Inc. boosted its holdings in Assembly Biosciences by 19.6% in the fourth quarter. BlackRock Inc. now owns 1,078,097 shares of the biopharmaceutical company’s stock valued at $48,784,000 after acquiring an additional 176,976 shares during the last quarter. Institutional investors and hedge funds own 77.26% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/03/15/assembly-biosciences-asmb-upgraded-by-bidaskclub-to-strong-buy.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.